Non-AIDS-defining malignancies in HIV-infected persons: Etiologic puzzles, epidemiologic perils, prevention opportunities

AIDS

Volumn 23, Issue 8, 2009, Pages 875-885

  Engels, Eric A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Hepatitis C virus; HIV AIDS; Human papillomavirus; Immunodeficiency; Tobacco use

Indexed keywords

ANTIRETROVIRUS AGENT; HEPATITIS B VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANUS CANCER; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CANCER; LUNG CANCER; PATIENT COUNSELING; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SKIN CANCER;

ALCOHOLISM; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANUS NEOPLASMS; DEVELOPED COUNTRIES; FEMALE; HIV INFECTIONS; HODGKIN DISEASE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; NEOPLASMS; RISK FACTORS; SEXUAL BEHAVIOR; SKIN NEOPLASMS; SMOKING;

EID: 67049156201     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328329216a     Document Type: Review

References (97)

1. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, Biggar RJ. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20: 1645-1654.
2. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mortal Wkly Rep 1992; 41:1-19.
3. IARC Monographs on the evaluation of carcinogenic risk to humans: Epstein-Barr virus and Kaposi's sarcoma herpesvirus/ human herpesvirus 8. International Agency for Research on Cancer; Lyon, France; 1997.
4. IARC Monographs on the evaluation of carcinogenic risk to humans: human papillomaviruses. International Agency for Research on Cancer, Lyon, France; 2007.
5. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007; 99:962-972.
6. Strickler HD, Burk RD, Fazzari M, Anastos K, Minkoff H, Massad LS, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005; 97:577-586.
7. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59-67.
8. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352:1725-1730.
9. Detels R, Tarwater P, Phair JP, Margolick J, Riddler SA, Munoz A. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 2001; 15:347-355.
10. Sterne JAC, Hernan MA, Ledergerber B, Tilling K, Weber R, Sendi P, et al., Swiss HIV Cohort Study. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366:378-384.
11. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97:425-432.
12. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy. The Swiss HIV cohort study. JAMA 1999; 282:2220-2226.
13. Shiels MS, Cole SR, Wegner S, Armenian H, Chmiel JS, Ganesan A, et al. Effect of HAART on incident cancer and noncancer AIDS events among male HIV seroconverters. J Acquir Immune Defic Syndr 2008; 48:485-490.
14. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123:187-194.
15. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148:728-736.
16. Glaser SL, Clarke CA, Gulley ML, Craig FE, DiGiuseppe JA, Dorfman RF, et al. Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998. Cancer 2003; 98:300-309.
17. Brock MV, Hooker CM, Engels EA, Moore RD, Gillison ML, Alberg AJ, et al. Delayed diagnosis and elevated mortality in an urban population with HIV infection and lung cancer: implications for patient care. J Acquir Immune Defic Syndr 2006; 43:47-55.
18. Chaturvedi AK, Pfeiffer RM, Chang L, Goedert JJ, Biggar RJ, Engels EA. Elevated risk of lung cancer among people with AIDS. AIDS 2007; 21:207-213.
19. Brau N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 2007; 47:527-537.
20. Puoti M, Bruno R, Soriano V, Donato F, Gaeta GB, Quinzan GP, et al. Hepatocellular carcinoma in HIV-infected patients: epi-demiological features, clinical presentation and outcome. AIDS 2004; 18:2285-2293.
21. Wistuba II, Behrens C, Milchgrub S, Virmani AK, Jagirdar J, Thomas B, et al. Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. JAMA 1998; 279:1554-1559.
22. Biggar RJ, Engels EA, Ly S, Kahn A, Schymura MJ, Sackoff J, et al. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 2005; 39:293-299.
23. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348:1681-1691.
24. Nguyen P, Vin-Christian K, Ming ME, Berger T. Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol 2002; 138: 758-763.
25. Maurer TA, Christian KV, Kerschmann RL, Berzin B, Palefsky JM, Payne D, et al. Cutaneous squamous cell carcinoma in human immunodeficiency virus-infected patients. A study of epidemiologic risk factors, human papillomavirus, and p53 expression. Arch Dermatol 1997; 133:577-583.
26. Engels EA, Brock MV, Chen J, Hooker CM, Gillison M, Moore RD. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006; 24:1383-1388.
27. Burkhalter JE, Springer CM, Chhabra R, Ostroff JS, Rapkin BD. Tobacco use and readiness to quit smoking in low-income HIV-infected persons. Nicotine Tob Res 2005; 7:511-522.
28. Gritz ER, Vidrine DJ, Lazev AB, Amick BC III, Arduino RC. Smoking behavior in a low-income multiethnic HIV/AIDS population. Nicotine Tob Res 2004; 6:71-77.
29. Stall RD, Greenwood GL, Acree M, Paul J, Coates TJ. Cigarette smoking among gay and bisexual men. Am J Public Health 1999; 89:1875-1878.
30. Kara J, Profeta G, Marantz PR, Karpel JP. Lung cancer in patients with immunodeficiency syndrome. Chest 1993; 103:410-413.
31. Kirk GD, Merlo C, O'Driscoll P, Mehta SH, Galai N, Vlahov D, et al. HIV infection is associated with an increased risk for lung cancer independent of smoking. J Infect Dis 2007; 45:103-110.
32. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006; 108:3786-3791.
33. Vilchez RA, Finch CJ, Jorgensen JL, Butel JS. The clinical epidemiology of Hodgkin lymphoma in HIV-infected patients in the highly active antiretroviral therapy (HAART) era. Medicine (Baltimore) 2003; 82:77-81.
34. Jaffe ES, Lee Harris N, Stein H, Vardiman JW. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
35. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002; 99:4283-4297.
36. Dolcetti R, Boiocchi M, Gloghini A, Carbone A. Pathogenetic and histogenetic features of HlV-associated Hodgkin's disease. Eur J Cancer 2001; 37:1276-1287.
37. FrischM, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001; 285:1736-1745.
38. Herida A, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin I, Rabaud C, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003; 21:3447-3453.
39. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis 2002; 35:1127-1134.
40. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-asso-ciated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92:1500-1510.
41. Palefsky JM, Holly EA, Ralston ML, Jay N, Berry JM, Darragh TM. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS 1998; 12:495-503.
42. Palefsky JM, Holly EA, Efirdc JT, Da Costa M, Jay N, Berry JM, Darragh TM. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS 2005; 19:1407-1414.
43. Piketty C, Darragh TM, Da Costa M, Bruneval P, Heard I, Kazatchkine MD, Palefsky JM. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med 2003; 138:453-459.
44. Holly EA, Ralston ML, Darragh TM, Greenblatt RM, Jay N, Palefsky JM. Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst 2001; 93:843-849.
45. Piketty C, Selinger-Leneman H, Grabar S, Duvivier C, Bonmarc-hand M, Abramowitz L, et al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 2008; 22:1203-1211.
46. Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS: impact of immunosuppression and incidence trends in the HAART era. J Natl Cancer Inst (in press).
47. Nordenvall C, Nyren O, Ye W. Elevated anal squamous cell carcinoma risk associated with benign inflammatory anal lesions. Cut 2006; 55:703-707.
48. D'Souza G, Wiley DJ, Li X, Chmiel JS, Margolick JB, Cranston RD, Jacobson L P. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2008; 48:491-499.
49. Chiao EY, Giordano TP, Palefsky JM, Tyring S, El Serag H. Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis 2006; 43:223-233.
50. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44:S6-S9.
51. Clifford GM, Rickenbach M, Polesel J, Dal Maso L, Steffen I, Ledergerber B, et al., Swiss HIV Cohort Study. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008; 22:2135-2141.
52. McGinnis KA, Fultz SL, Skanderson M, Conigliaro J, Bryant K, Justice AC. Hepatocellular carcinoma and non-Hodgkin's lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse. J Clin Oncol 2006; 24:5005-5009.
53. Engels EA, Frisch M, Lubin JH, Gail MH, Biggar RJ, Goedert JJ. Prevalence of hepatitis C virus infection and risk for hepatocellular carcinoma and non-Hodgkin lymphoma in AIDS. J Acquir Immune Defic Syndr 2002; 31:536-541.
54. Giordano TP, Kramer JR, Souchek J, Richardson P, El Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med 2004; 164:2349-2354.
55. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiolo-pical studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998; 75:347-354.
56. Weber R, Sabin CA, Friis-Moller N, Reiss P, El Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
57. Goedert JJ, Eyster ME, Lederman MM, Mandalaki T, De Moer-loose P, White GC, et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002; 100:1584-1589.
58. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73.
59. Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29:1306-1310.
60. Kramer JR, Giordano TP, Souchek J, Richardson P, Hwang LY, El Serag HB. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Castroenterol 2005; 100:56-63.
61. Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer S. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol 2007; 165:1143-1153.
62. LeBoit PE, Burg G, Weedon D, Sarasain A. World Health Organization Classification of Tumours. Pathology and genetics of skin tumours. Lyon, France: IARC Press; 2006.
63. Gruber SB, Armstrong BK. Cutaneous and ocular melanoma. In: Schottenfeld D, Fraumeni Jr J. editors. Cancer epidemiology, prevention New York: Oxford University Press; 2006. pp. 1196-1229.
64. Karagas MR, Weinstock MA, Nelson HH. Keratinocyte carcinomas (basal and squamous cell carcinomas of the skin). In: Schottenfeld D, Fraumeni Jr J. editors. Cancer epidemiology and prevention New York: Oxford University Press; 2006. pp. 1230-1250.
65. Ramsay HM, Fryer AA, Hawley CM, Smith AC, Harden PN. Nonmelanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol 2002; 147:950-956.
66. Burgi A, Brodine S, Wegner S, Milazzo M, Wallace MR, Spoo-ner K, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005; 104:1505-1511.
67. Crum-Cianflone N, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS 2009; 23:41-50.
68. Overly WL, Jakubek DJ. Multiple squamous cell carcinomas and human immunodeficiency virus infection. Ann Intern Med 1987; 106:334.
69. Lobo DV, Chu P, Grekin RC, Berger TG. Nonmelanoma skin cancers and infection with the human immunodeficiency virus. Arch Dermatol 1992; 128:623-627.
70. Lanoy E, Dores GM, Madeleine MM, Toro JR, Fraumeni JF Jr, Engels EA. Epidemiology of nonkeratinocytic skin cancers among persons with acquired immunodeficiency syndrome in the U.S. AIDS 23:385-393.
71. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008; 319:1096-1100.
72. Moosa MR, Cralla J. Skin cancer in renal allograft recipients: experience in different ethnic groups residing in the same geographical region. Clin Transplant 2005; 19:735-741.
73. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-998.
74. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, Thomas DL. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-1926.
75. Engels EA. Inflammation in the development of lung cancer: epidemiological evidence. Expert Rev Anticancer Ther 2008; 8:605-615.
76. Agostini C, Sancetta R, Cerutti A, Semenzato G. Alveolar macrophages as a cell source of cytokine hyperproduction in HIV-related interstitial lung disease. J Leukoc Biol 1995; 58:495-500.
77. Bower M, Nelson M, Young AM, Thirlwel I C, Newsom-Davis T, Mandalia S, et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol 2005; 23:5224-5228.
78. Weir A, Wansbrough-Jones M. Mucosal Kaposi's sarcoma following protease inhibitor therapy in an HIV-infected patient. AIDS 1997; 11:1895-1896.
79. Martin JN, Laker M, Kambugu A, Janka D, Orem J, Mwaka A, et al. Kaposi's sarcoma-associated immune reconstitution inflammatory syndrome (KS-IRIS) in Africa: initial findings from a prospective evaluation [abstract]. International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies; Bethesda, Maryland; 2008.
80. Olivero OA. Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors. Environ Mol Mutagen 2007; 48:215-223.
81. The Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. Am J Prev Med 2008; 35:158-176.
82. Wiley DJ, Harper DM, Elashoff D, Silverberg MJ, Kaestle C, Cook RL, et al. How condom use, number of receptive anal intercourse partners and history of external genital warts predict risk for external anal warts. Int J STD AIDS 2005; 16:203-211.
83. Chang MH, Shau WY, Chen CJ, Wu TC, Kong MS, Liang DC, et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA 2000; 284:3040-3042.
84. Laurence JC. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med 2005; 118:75S-83S.
85. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928-1943.
86. Palefsky JM, Gillison ML, Stickler HD. Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine 2006; 24:S3-140-S3/ 146.
87. Sulkowski MS. Management of hepatic complications in HIV-infected persons. J Infect Dis 2008; 197:S279-S293.
88. Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML. High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience. Dis Colon Rectum 2008; 51:829-835.
89. Anderson JS, Vajdic C, Grulich AE. Is screening for anal cancer warranted in homosexual men? Sex Health 2004; 1:137-140.
90. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA 1999; 281:1822-1829.
91. Naucler P, Ryd W, Tomberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357:1589-1597.
92. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002; 47:1-17.
93. Gohagan JK, Marcus PM, Fagerstrom RM, Pinsky PF, Kramer BS, Prorok PC, et al. Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer 2005; 47:9-15.
94. Oken MM, Marcus PM, Hu P, Beck TM, Hocking W, Kvale PA, et al. Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Natl Cancer Inst 2005; 97:1832-1839.
95. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona - 2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421-430.
96. Bruno R, Puoti M, Sacchi P, Filice C, Carosi G, Filice G. Management of hepatocellular carcinoma in human immunodeficiency virus-infected patients. J Hepatol 2006; 4b4:S146-S150.
97. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 3 November 2008. Available at http:// aidsinfo.nih.gov/. [Accessed 24 December 2008]; 2008. U.S. Department of Health and Human Services.